Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) Stock Competitors & Peer Comparison
See (NBIX) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NBIX | $131.31 | -0.24% | 13B | 38.85 | $3.38 | N/A |
| ZTS | $153.06 | +0.41% | 67.8B | 26.34 | $5.81 | +1.27% |
| TAK | $14.80 | +0.20% | 46.8B | 51.05 | $0.29 | +4.07% |
| HLN | $9.70 | +0.10% | 43.6B | 21.57 | $0.45 | +1.73% |
| TEVA | $17.54 | +1.92% | 20.1B | -117.00 | -$0.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| VTRS | $10.69 | +2.69% | 12.5B | -3.65 | -$2.93 | +4.48% |
| RDY | $14.11 | -1.05% | 11.8B | 18.10 | $0.78 | +0.64% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $18.00 | +1.07% | 8.9B | 20.44 | $0.88 | N/A |
Stock Comparison
NBIX vs ZTS Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ZTS has a market cap of 67.8B. Regarding current trading prices, NBIX is priced at $131.31, while ZTS trades at $153.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ZTS's P/E ratio is 26.34. In terms of profitability, NBIX's ROE is +0.13%, compared to ZTS's ROE of +0.53%. Regarding short-term risk, NBIX is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ZTS's competition here
NBIX vs TAK Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TAK has a market cap of 46.8B. Regarding current trading prices, NBIX is priced at $131.31, while TAK trades at $14.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TAK's P/E ratio is 51.05. In terms of profitability, NBIX's ROE is +0.13%, compared to TAK's ROE of +0.01%. Regarding short-term risk, NBIX is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check TAK's competition here
NBIX vs HLN Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, HLN has a market cap of 43.6B. Regarding current trading prices, NBIX is priced at $131.31, while HLN trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas HLN's P/E ratio is 21.57. In terms of profitability, NBIX's ROE is +0.13%, compared to HLN's ROE of +0.09%. Regarding short-term risk, NBIX is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check HLN's competition here
NBIX vs TEVA Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TEVA has a market cap of 20.1B. Regarding current trading prices, NBIX is priced at $131.31, while TEVA trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TEVA's P/E ratio is -117.00. In terms of profitability, NBIX's ROE is +0.13%, compared to TEVA's ROE of -0.03%. Regarding short-term risk, NBIX is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check TEVA's competition here
NBIX vs ITCI Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, NBIX is priced at $131.31, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ITCI's P/E ratio is -180.64. In terms of profitability, NBIX's ROE is +0.13%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, NBIX is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check ITCI's competition here
NBIX vs VTRS Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, VTRS has a market cap of 12.5B. Regarding current trading prices, NBIX is priced at $131.31, while VTRS trades at $10.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas VTRS's P/E ratio is -3.65. In terms of profitability, NBIX's ROE is +0.13%, compared to VTRS's ROE of -0.20%. Regarding short-term risk, NBIX is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check VTRS's competition here
NBIX vs RDY Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, RDY has a market cap of 11.8B. Regarding current trading prices, NBIX is priced at $131.31, while RDY trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas RDY's P/E ratio is 18.10. In terms of profitability, NBIX's ROE is +0.13%, compared to RDY's ROE of +0.17%. Regarding short-term risk, NBIX is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check RDY's competition here
NBIX vs CTLT Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, NBIX is priced at $131.31, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas CTLT's P/E ratio is -27.84. In terms of profitability, NBIX's ROE is +0.13%, compared to CTLT's ROE of -0.06%. Regarding short-term risk, NBIX is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check CTLT's competition here
NBIX vs ELAN Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ELAN has a market cap of 8.9B. Regarding current trading prices, NBIX is priced at $131.31, while ELAN trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ELAN's P/E ratio is 20.44. In terms of profitability, NBIX's ROE is +0.13%, compared to ELAN's ROE of +0.07%. Regarding short-term risk, NBIX is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ELAN's competition here
NBIX vs RGC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, RGC has a market cap of 6.3B. Regarding current trading prices, NBIX is priced at $131.31, while RGC trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas RGC's P/E ratio is -1270.00. In terms of profitability, NBIX's ROE is +0.13%, compared to RGC's ROE of -0.50%. Regarding short-term risk, NBIX is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check RGC's competition here
NBIX vs LNTH Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, LNTH has a market cap of 3.7B. Regarding current trading prices, NBIX is priced at $131.31, while LNTH trades at $54.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas LNTH's P/E ratio is 14.49. In terms of profitability, NBIX's ROE is +0.13%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, NBIX is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check LNTH's competition here
NBIX vs PRGO Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, PRGO has a market cap of 3.2B. Regarding current trading prices, NBIX is priced at $131.31, while PRGO trades at $23.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas PRGO's P/E ratio is -53.53. In terms of profitability, NBIX's ROE is +0.13%, compared to PRGO's ROE of -0.02%. Regarding short-term risk, NBIX is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check PRGO's competition here
NBIX vs AMRX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, AMRX has a market cap of 2.9B. Regarding current trading prices, NBIX is priced at $131.31, while AMRX trades at $9.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas AMRX's P/E ratio is 939.00. In terms of profitability, NBIX's ROE is +0.13%, compared to AMRX's ROE of -0.03%. Regarding short-term risk, NBIX is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check AMRX's competition here
NBIX vs INDV Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, INDV has a market cap of 2.9B. Regarding current trading prices, NBIX is priced at $131.31, while INDV trades at $23.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas INDV's P/E ratio is 28.60. In terms of profitability, NBIX's ROE is +0.13%, compared to INDV's ROE of -0.48%. Regarding short-term risk, NBIX is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check INDV's competition here
NBIX vs BHC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, BHC has a market cap of 2.8B. Regarding current trading prices, NBIX is priced at $131.31, while BHC trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas BHC's P/E ratio is 28.90. In terms of profitability, NBIX's ROE is +0.13%, compared to BHC's ROE of -0.09%. Regarding short-term risk, NBIX is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check BHC's competition here
NBIX vs HCM Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, NBIX is priced at $131.31, while HCM trades at $15.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas HCM's P/E ratio is 5.99. In terms of profitability, NBIX's ROE is +0.13%, compared to HCM's ROE of +0.05%. Regarding short-term risk, NBIX is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check HCM's competition here
NBIX vs ALVOW Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ALVOW has a market cap of 2.7B. Regarding current trading prices, NBIX is priced at $131.31, while ALVOW trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ALVOW's P/E ratio is N/A. In terms of profitability, NBIX's ROE is +0.13%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, NBIX is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ALVOW's competition here
NBIX vs ALVO Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ALVO has a market cap of 2.6B. Regarding current trading prices, NBIX is priced at $131.31, while ALVO trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ALVO's P/E ratio is 22.91. In terms of profitability, NBIX's ROE is +0.13%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, NBIX is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ALVO's competition here
NBIX vs SUPN Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SUPN has a market cap of 2.4B. Regarding current trading prices, NBIX is priced at $131.31, while SUPN trades at $42.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SUPN's P/E ratio is 36.67. In terms of profitability, NBIX's ROE is +0.13%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, NBIX is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check SUPN's competition here
NBIX vs DCPH Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, NBIX is priced at $131.31, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas DCPH's P/E ratio is -11.58. In terms of profitability, NBIX's ROE is +0.13%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, NBIX is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check DCPH's competition here
NBIX vs ANIP Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ANIP has a market cap of 2B. Regarding current trading prices, NBIX is priced at $131.31, while ANIP trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ANIP's P/E ratio is -130.43. In terms of profitability, NBIX's ROE is +0.13%, compared to ANIP's ROE of -0.03%. Regarding short-term risk, NBIX is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ANIP's competition here
NBIX vs EMBCV Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, NBIX is priced at $131.31, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas EMBCV's P/E ratio is N/A. In terms of profitability, NBIX's ROE is +0.13%, compared to EMBCV's ROE of +0.71%. Regarding short-term risk, NBIX is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check EMBCV's competition here
NBIX vs TARO Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, NBIX is priced at $131.31, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TARO's P/E ratio is 30.05. In terms of profitability, NBIX's ROE is +0.13%, compared to TARO's ROE of +0.03%. Regarding short-term risk, NBIX is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check TARO's competition here
NBIX vs BGM Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, BGM has a market cap of 1.5B. Regarding current trading prices, NBIX is priced at $131.31, while BGM trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas BGM's P/E ratio is -26.12. In terms of profitability, NBIX's ROE is +0.13%, compared to BGM's ROE of -0.03%. Regarding short-term risk, NBIX is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check BGM's competition here
NBIX vs HROW Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, NBIX is priced at $131.31, while HROW trades at $40.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas HROW's P/E ratio is -142.89. In terms of profitability, NBIX's ROE is +0.13%, compared to HROW's ROE of -0.18%. Regarding short-term risk, NBIX is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check HROW's competition here
NBIX vs AMPH Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, AMPH has a market cap of 1.4B. Regarding current trading prices, NBIX is priced at $131.31, while AMPH trades at $30.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas AMPH's P/E ratio is 11.31. In terms of profitability, NBIX's ROE is +0.13%, compared to AMPH's ROE of +0.18%. Regarding short-term risk, NBIX is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check AMPH's competition here
NBIX vs EVO Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, EVO has a market cap of 1.4B. Regarding current trading prices, NBIX is priced at $131.31, while EVO trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas EVO's P/E ratio is -7.49. In terms of profitability, NBIX's ROE is +0.13%, compared to EVO's ROE of -0.22%. Regarding short-term risk, NBIX is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check EVO's competition here
NBIX vs AVDL Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, AVDL has a market cap of 1.3B. Regarding current trading prices, NBIX is priced at $131.31, while AVDL trades at $13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas AVDL's P/E ratio is -675.00. In terms of profitability, NBIX's ROE is +0.13%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, NBIX is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check AVDL's competition here
NBIX vs TLRY Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TLRY has a market cap of 1.3B. Regarding current trading prices, NBIX is priced at $131.31, while TLRY trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TLRY's P/E ratio is -0.48. In terms of profitability, NBIX's ROE is +0.13%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, NBIX is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check TLRY's competition here
NBIX vs DVAX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, NBIX is priced at $131.31, while DVAX trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas DVAX's P/E ratio is -23.60. In terms of profitability, NBIX's ROE is +0.13%, compared to DVAX's ROE of -0.09%. Regarding short-term risk, NBIX is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check DVAX's competition here
NBIX vs PAHC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, NBIX is priced at $131.31, while PAHC trades at $30.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas PAHC's P/E ratio is 39.19. In terms of profitability, NBIX's ROE is +0.13%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, NBIX is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check PAHC's competition here
NBIX vs COLL Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, NBIX is priced at $131.31, while COLL trades at $37.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas COLL's P/E ratio is 35.06. In terms of profitability, NBIX's ROE is +0.13%, compared to COLL's ROE of +0.19%. Regarding short-term risk, NBIX is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check COLL's competition here
NBIX vs PCRX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, NBIX is priced at $131.31, while PCRX trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas PCRX's P/E ratio is -9.09. In terms of profitability, NBIX's ROE is +0.13%, compared to PCRX's ROE of -0.17%. Regarding short-term risk, NBIX is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check PCRX's competition here
NBIX vs CRON Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, CRON has a market cap of 965M. Regarding current trading prices, NBIX is priced at $131.31, while CRON trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas CRON's P/E ratio is 50.40. In terms of profitability, NBIX's ROE is +0.13%, compared to CRON's ROE of +0.02%. Regarding short-term risk, NBIX is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check CRON's competition here
NBIX vs PETQ Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, NBIX is priced at $131.31, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas PETQ's P/E ratio is 83.73. In terms of profitability, NBIX's ROE is +0.13%, compared to PETQ's ROE of +0.12%. Regarding short-term risk, NBIX is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check PETQ's competition here
NBIX vs EMBC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, EMBC has a market cap of 811.2M. Regarding current trading prices, NBIX is priced at $131.31, while EMBC trades at $13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas EMBC's P/E ratio is 9.77. In terms of profitability, NBIX's ROE is +0.13%, compared to EMBC's ROE of -0.11%. Regarding short-term risk, NBIX is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check EMBC's competition here
NBIX vs SIGA Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SIGA has a market cap of 614.4M. Regarding current trading prices, NBIX is priced at $131.31, while SIGA trades at $8.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SIGA's P/E ratio is 7.53. In terms of profitability, NBIX's ROE is +0.13%, compared to SIGA's ROE of +0.41%. Regarding short-term risk, NBIX is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check SIGA's competition here
NBIX vs ORGO Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ORGO has a market cap of 596.2M. Regarding current trading prices, NBIX is priced at $131.31, while ORGO trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ORGO's P/E ratio is -33.57. In terms of profitability, NBIX's ROE is +0.13%, compared to ORGO's ROE of -0.03%. Regarding short-term risk, NBIX is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ORGO's competition here
NBIX vs BDSI Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, NBIX is priced at $131.31, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas BDSI's P/E ratio is 6.82. In terms of profitability, NBIX's ROE is +0.13%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, NBIX is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check BDSI's competition here
NBIX vs SNDL Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SNDL has a market cap of 543.1M. Regarding current trading prices, NBIX is priced at $131.31, while SNDL trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SNDL's P/E ratio is -7.54. In terms of profitability, NBIX's ROE is +0.13%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, NBIX is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check SNDL's competition here
NBIX vs EBS Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, EBS has a market cap of 470.6M. Regarding current trading prices, NBIX is priced at $131.31, while EBS trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas EBS's P/E ratio is 3.37. In terms of profitability, NBIX's ROE is +0.13%, compared to EBS's ROE of +0.27%. Regarding short-term risk, NBIX is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check EBS's competition here
NBIX vs KMDA Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, KMDA has a market cap of 419.8M. Regarding current trading prices, NBIX is priced at $131.31, while KMDA trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas KMDA's P/E ratio is 26.07. In terms of profitability, NBIX's ROE is +0.13%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, NBIX is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check KMDA's competition here
NBIX vs EOLS Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, EOLS has a market cap of 414M. Regarding current trading prices, NBIX is priced at $131.31, while EOLS trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas EOLS's P/E ratio is -6.60. In terms of profitability, NBIX's ROE is +0.13%, compared to EOLS's ROE of +17.91%. Regarding short-term risk, NBIX is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check EOLS's competition here
NBIX vs ESPR Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ESPR has a market cap of 410.3M. Regarding current trading prices, NBIX is priced at $131.31, while ESPR trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ESPR's P/E ratio is -4.14. In terms of profitability, NBIX's ROE is +0.13%, compared to ESPR's ROE of +0.32%. Regarding short-term risk, NBIX is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ESPR's competition here
NBIX vs AQST Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, AQST has a market cap of 409.9M. Regarding current trading prices, NBIX is priced at $131.31, while AQST trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas AQST's P/E ratio is -5.96. In terms of profitability, NBIX's ROE is +0.13%, compared to AQST's ROE of +1.09%. Regarding short-term risk, NBIX is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check AQST's competition here
NBIX vs ZYBT Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ZYBT has a market cap of 360.2M. Regarding current trading prices, NBIX is priced at $131.31, while ZYBT trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ZYBT's P/E ratio is 253.33. In terms of profitability, NBIX's ROE is +0.13%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, NBIX is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ZYBT's competition here
NBIX vs CGC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, CGC has a market cap of 339.2M. Regarding current trading prices, NBIX is priced at $131.31, while CGC trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas CGC's P/E ratio is -0.49. In terms of profitability, NBIX's ROE is +0.13%, compared to CGC's ROE of -0.99%. Regarding short-term risk, NBIX is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check CGC's competition here
NBIX vs ACB Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ACB has a market cap of 303.2M. Regarding current trading prices, NBIX is priced at $131.31, while ACB trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ACB's P/E ratio is -134.75. In terms of profitability, NBIX's ROE is +0.13%, compared to ACB's ROE of +0.00%. Regarding short-term risk, NBIX is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ACB's competition here
NBIX vs ALIM Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, NBIX is priced at $131.31, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ALIM's P/E ratio is 5.28. In terms of profitability, NBIX's ROE is +0.13%, compared to ALIM's ROE of -0.24%. Regarding short-term risk, NBIX is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check ALIM's competition here
NBIX vs LFCR Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, LFCR has a market cap of 277.6M. Regarding current trading prices, NBIX is priced at $131.31, while LFCR trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas LFCR's P/E ratio is -5.84. In terms of profitability, NBIX's ROE is +0.13%, compared to LFCR's ROE of -2.53%. Regarding short-term risk, NBIX is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check LFCR's competition here
NBIX vs LNDC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, NBIX is priced at $131.31, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas LNDC's P/E ratio is -4.04. In terms of profitability, NBIX's ROE is +0.13%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, NBIX is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check LNDC's competition here
NBIX vs TKNO Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TKNO has a market cap of 256.9M. Regarding current trading prices, NBIX is priced at $131.31, while TKNO trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TKNO's P/E ratio is -12.31. In terms of profitability, NBIX's ROE is +0.13%, compared to TKNO's ROE of -0.27%. Regarding short-term risk, NBIX is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check TKNO's competition here
NBIX vs TYHT Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, NBIX is priced at $131.31, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TYHT's P/E ratio is -1.61. In terms of profitability, NBIX's ROE is +0.13%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, NBIX is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check TYHT's competition here
NBIX vs OGI Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, OGI has a market cap of 208.9M. Regarding current trading prices, NBIX is priced at $131.31, while OGI trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas OGI's P/E ratio is 12.00. In terms of profitability, NBIX's ROE is +0.13%, compared to OGI's ROE of +0.05%. Regarding short-term risk, NBIX is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check OGI's competition here
NBIX vs SXTC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SXTC has a market cap of 185.6M. Regarding current trading prices, NBIX is priced at $131.31, while SXTC trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SXTC's P/E ratio is -0.69. In terms of profitability, NBIX's ROE is +0.13%, compared to SXTC's ROE of +0.17%. Regarding short-term risk, NBIX is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check SXTC's competition here
NBIX vs REPH Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, NBIX is priced at $131.31, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas REPH's P/E ratio is -8.04. In terms of profitability, NBIX's ROE is +0.13%, compared to REPH's ROE of -0.22%. Regarding short-term risk, NBIX is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check REPH's competition here
NBIX vs IRWD Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, IRWD has a market cap of 173.8M. Regarding current trading prices, NBIX is priced at $131.31, while IRWD trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas IRWD's P/E ratio is -21.40. In terms of profitability, NBIX's ROE is +0.13%, compared to IRWD's ROE of +0.03%. Regarding short-term risk, NBIX is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check IRWD's competition here
NBIX vs DERM Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, DERM has a market cap of 169.1M. Regarding current trading prices, NBIX is priced at $131.31, while DERM trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas DERM's P/E ratio is -19.62. In terms of profitability, NBIX's ROE is +0.13%, compared to DERM's ROE of -0.49%. Regarding short-term risk, NBIX is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check DERM's competition here
NBIX vs BIOA Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, BIOA has a market cap of 159.9M. Regarding current trading prices, NBIX is priced at $131.31, while BIOA trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas BIOA's P/E ratio is -0.65. In terms of profitability, NBIX's ROE is +0.13%, compared to BIOA's ROE of -0.25%. Regarding short-term risk, NBIX is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check BIOA's competition here
NBIX vs THTX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, THTX has a market cap of 148.1M. Regarding current trading prices, NBIX is priced at $131.31, while THTX trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas THTX's P/E ratio is -16.95. In terms of profitability, NBIX's ROE is +0.13%, compared to THTX's ROE of +0.38%. Regarding short-term risk, NBIX is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check THTX's competition here
NBIX vs SCTL Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, NBIX is priced at $131.31, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SCTL's P/E ratio is -7.86. In terms of profitability, NBIX's ROE is +0.13%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, NBIX is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check SCTL's competition here
NBIX vs PROC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, NBIX is priced at $131.31, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas PROC's P/E ratio is 1.53. In terms of profitability, NBIX's ROE is +0.13%, compared to PROC's ROE of -2.22%. Regarding short-term risk, NBIX is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check PROC's competition here
NBIX vs CRDL Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, CRDL has a market cap of 110.8M. Regarding current trading prices, NBIX is priced at $131.31, while CRDL trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas CRDL's P/E ratio is -3.94. In terms of profitability, NBIX's ROE is +0.13%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, NBIX is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check CRDL's competition here
NBIX vs OPTN Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, NBIX is priced at $131.31, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas OPTN's P/E ratio is -4.42. In terms of profitability, NBIX's ROE is +0.13%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, NBIX is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check OPTN's competition here
NBIX vs ZOM Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, NBIX is priced at $131.31, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ZOM's P/E ratio is -1.62. In terms of profitability, NBIX's ROE is +0.13%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, NBIX is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ZOM's competition here
NBIX vs INCR Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, INCR has a market cap of 90.5M. Regarding current trading prices, NBIX is priced at $131.31, while INCR trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas INCR's P/E ratio is -3.86. In terms of profitability, NBIX's ROE is +0.13%, compared to INCR's ROE of -0.15%. Regarding short-term risk, NBIX is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check INCR's competition here
NBIX vs GRVI Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, NBIX is priced at $131.31, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas GRVI's P/E ratio is 26.05. In terms of profitability, NBIX's ROE is +0.13%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, NBIX is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check GRVI's competition here
NBIX vs ASRT Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ASRT has a market cap of 78.8M. Regarding current trading prices, NBIX is priced at $131.31, while ASRT trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ASRT's P/E ratio is -1.82. In terms of profitability, NBIX's ROE is +0.13%, compared to ASRT's ROE of -0.38%. Regarding short-term risk, NBIX is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ASRT's competition here
NBIX vs QNTM Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, QNTM has a market cap of 76.5M. Regarding current trading prices, NBIX is priced at $131.31, while QNTM trades at $22.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas QNTM's P/E ratio is -1.96. In terms of profitability, NBIX's ROE is +0.13%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, NBIX is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check QNTM's competition here
NBIX vs ZYNE Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, NBIX is priced at $131.31, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, NBIX's ROE is +0.13%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, NBIX is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ZYNE's competition here
NBIX vs SSIC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, NBIX is priced at $131.31, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SSIC's P/E ratio is 11.93. In terms of profitability, NBIX's ROE is +0.13%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, NBIX is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check SSIC's competition here
NBIX vs VLNS Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, NBIX is priced at $131.31, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas VLNS's P/E ratio is -1.03. In terms of profitability, NBIX's ROE is +0.13%, compared to VLNS's ROE of N/A. Regarding short-term risk, NBIX is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check VLNS's competition here
NBIX vs DRRX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, DRRX has a market cap of 59M. Regarding current trading prices, NBIX is priced at $131.31, while DRRX trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas DRRX's P/E ratio is -4.32. In terms of profitability, NBIX's ROE is +0.13%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, NBIX is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check DRRX's competition here
NBIX vs KALA Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, KALA has a market cap of 56.7M. Regarding current trading prices, NBIX is priced at $131.31, while KALA trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas KALA's P/E ratio is -1.35. In terms of profitability, NBIX's ROE is +0.13%, compared to KALA's ROE of -6.86%. Regarding short-term risk, NBIX is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check KALA's competition here
NBIX vs JUPW Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, NBIX is priced at $131.31, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas JUPW's P/E ratio is -2.41. In terms of profitability, NBIX's ROE is +0.13%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, NBIX is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check JUPW's competition here
NBIX vs CPIX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, CPIX has a market cap of 44.7M. Regarding current trading prices, NBIX is priced at $131.31, while CPIX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas CPIX's P/E ratio is -13.59. In terms of profitability, NBIX's ROE is +0.13%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, NBIX is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check CPIX's competition here
NBIX vs EGRX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, EGRX has a market cap of 41.6M. Regarding current trading prices, NBIX is priced at $131.31, while EGRX trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas EGRX's P/E ratio is 3.76. In terms of profitability, NBIX's ROE is +0.13%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, NBIX is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check EGRX's competition here
NBIX vs QLI Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, NBIX is priced at $131.31, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas QLI's P/E ratio is -4.92. In terms of profitability, NBIX's ROE is +0.13%, compared to QLI's ROE of -0.16%. Regarding short-term risk, NBIX is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check QLI's competition here
NBIX vs RMTI Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, RMTI has a market cap of 35.9M. Regarding current trading prices, NBIX is priced at $131.31, while RMTI trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas RMTI's P/E ratio is -105.00. In terms of profitability, NBIX's ROE is +0.13%, compared to RMTI's ROE of -0.07%. Regarding short-term risk, NBIX is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check RMTI's competition here
NBIX vs SCYX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SCYX has a market cap of 31.3M. Regarding current trading prices, NBIX is priced at $131.31, while SCYX trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SCYX's P/E ratio is -1.43. In terms of profitability, NBIX's ROE is +0.13%, compared to SCYX's ROE of -0.37%. Regarding short-term risk, NBIX is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check SCYX's competition here
NBIX vs HEXO Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, NBIX is priced at $131.31, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas HEXO's P/E ratio is -0.26. In terms of profitability, NBIX's ROE is +0.13%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, NBIX is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check HEXO's competition here
NBIX vs COSM Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, COSM has a market cap of 25.9M. Regarding current trading prices, NBIX is priced at $131.31, while COSM trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas COSM's P/E ratio is -0.81. In terms of profitability, NBIX's ROE is +0.13%, compared to COSM's ROE of -0.51%. Regarding short-term risk, NBIX is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check COSM's competition here
NBIX vs CYTH Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, NBIX is priced at $131.31, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas CYTH's P/E ratio is -0.80. In terms of profitability, NBIX's ROE is +0.13%, compared to CYTH's ROE of +3.20%. Regarding short-term risk, NBIX is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for NBIX.Check CYTH's competition here
NBIX vs ACRX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, NBIX is priced at $131.31, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas ACRX's P/E ratio is -0.31. In terms of profitability, NBIX's ROE is +0.13%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, NBIX is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check ACRX's competition here
NBIX vs GELS Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, GELS has a market cap of 14.2M. Regarding current trading prices, NBIX is priced at $131.31, while GELS trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas GELS's P/E ratio is -4.06. In terms of profitability, NBIX's ROE is +0.13%, compared to GELS's ROE of -0.07%. Regarding short-term risk, NBIX is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check GELS's competition here
NBIX vs PRPH Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, PRPH has a market cap of 13.8M. Regarding current trading prices, NBIX is priced at $131.31, while PRPH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas PRPH's P/E ratio is -0.15. In terms of profitability, NBIX's ROE is +0.13%, compared to PRPH's ROE of -2.30%. Regarding short-term risk, NBIX is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check PRPH's competition here
NBIX vs FLGC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, FLGC has a market cap of 13.6M. Regarding current trading prices, NBIX is priced at $131.31, while FLGC trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas FLGC's P/E ratio is -0.68. In terms of profitability, NBIX's ROE is +0.13%, compared to FLGC's ROE of -2.98%. Regarding short-term risk, NBIX is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check FLGC's competition here
NBIX vs AYTU Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, AYTU has a market cap of 13.5M. Regarding current trading prices, NBIX is priced at $131.31, while AYTU trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas AYTU's P/E ratio is -1.47. In terms of profitability, NBIX's ROE is +0.13%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, NBIX is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check AYTU's competition here
NBIX vs TXMD Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TXMD has a market cap of 13.3M. Regarding current trading prices, NBIX is priced at $131.31, while TXMD trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TXMD's P/E ratio is -23.00. In terms of profitability, NBIX's ROE is +0.13%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, NBIX is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check TXMD's competition here
NBIX vs IXHL Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, IXHL has a market cap of 11.6M. Regarding current trading prices, NBIX is priced at $131.31, while IXHL trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas IXHL's P/E ratio is -0.32. In terms of profitability, NBIX's ROE is +0.13%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, NBIX is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check IXHL's competition here
NBIX vs AGRX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, NBIX is priced at $131.31, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas AGRX's P/E ratio is -0.89. In terms of profitability, NBIX's ROE is +0.13%, compared to AGRX's ROE of +0.66%. Regarding short-term risk, NBIX is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check AGRX's competition here
NBIX vs BFRI Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, BFRI has a market cap of 9.6M. Regarding current trading prices, NBIX is priced at $131.31, while BFRI trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas BFRI's P/E ratio is -1.17. In terms of profitability, NBIX's ROE is +0.13%, compared to BFRI's ROE of -11.51%. Regarding short-term risk, NBIX is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check BFRI's competition here
NBIX vs TLPH Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, TLPH has a market cap of 8.8M. Regarding current trading prices, NBIX is priced at $131.31, while TLPH trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas TLPH's P/E ratio is -0.98. In terms of profitability, NBIX's ROE is +0.13%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, NBIX is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check TLPH's competition here
NBIX vs BFRIW Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, BFRIW has a market cap of 8.7M. Regarding current trading prices, NBIX is priced at $131.31, while BFRIW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas BFRIW's P/E ratio is -0.09. In terms of profitability, NBIX's ROE is +0.13%, compared to BFRIW's ROE of -11.51%. Regarding short-term risk, NBIX is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check BFRIW's competition here
NBIX vs SNOA Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, SNOA has a market cap of 8.6M. Regarding current trading prices, NBIX is priced at $131.31, while SNOA trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas SNOA's P/E ratio is -2.38. In terms of profitability, NBIX's ROE is +0.13%, compared to SNOA's ROE of -0.76%. Regarding short-term risk, NBIX is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check SNOA's competition here
NBIX vs NLTX Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, NBIX is priced at $131.31, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas NLTX's P/E ratio is -0.28. In terms of profitability, NBIX's ROE is +0.13%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, NBIX is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check NLTX's competition here
NBIX vs IMCC Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, IMCC has a market cap of 8M. Regarding current trading prices, NBIX is priced at $131.31, while IMCC trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas IMCC's P/E ratio is -5.31. In terms of profitability, NBIX's ROE is +0.13%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, NBIX is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check IMCC's competition here
NBIX vs EVOK Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, EVOK has a market cap of 7.7M. Regarding current trading prices, NBIX is priced at $131.31, while EVOK trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas EVOK's P/E ratio is -4.18. In terms of profitability, NBIX's ROE is +0.13%, compared to EVOK's ROE of -1.02%. Regarding short-term risk, NBIX is less volatile compared to EVOK. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check EVOK's competition here
NBIX vs YCBD Comparison August 2025
NBIX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NBIX stands at 13B. In comparison, YCBD has a market cap of 7.5M. Regarding current trading prices, NBIX is priced at $131.31, while YCBD trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NBIX currently has a P/E ratio of 38.85, whereas YCBD's P/E ratio is 0.01. In terms of profitability, NBIX's ROE is +0.13%, compared to YCBD's ROE of -0.62%. Regarding short-term risk, NBIX is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for NBIX.Check YCBD's competition here